March 2021 | Page 17 of 17

Merck Builds on Leadership in Head and Neck Cancer Through Worldwide Licensing Agreement …

By HealthClot Moderator
March 1, 2021
0

Merck Builds on Leadership in Head and Neck Cancer Through Worldwide Licensing Agreement … – Xevinapant is the first Inhibitor of Apoptosis Proteins antagonist with FDA Breakthrough Therapy Designation for previously untreated locally advanced squamous cell carcinoma of the head and neck, in combination with current standard of care – A Phase II trial reported […]

No hiding place for cancer

By HealthClot Moderator
March 1, 2021
0

No hiding place for cancer European researchers have made a breakthrough paving the way for the development of precision treatments that can destroy cancers at source. Until now the similarity between cancer cells and healthy cells has made destroying one while protecting the other tough. But a new method developed by teams from the Centre […]

By HealthClot Moderator
March 1, 2021
0

FY2021 EPS Estimates for Fate Therapeutics, Inc. (NASDAQ:FATE) Decreased by Cantor Fitzgerald Fate Therapeutics, Inc. (NASDAQ:FATE) – Stock analysts at Cantor Fitzgerald dropped their FY2021 earnings estimates for shares of Fate Therapeutics in a note issued to investors on Thursday, February 25th. Cantor Fitzgerald analyst A. Young now anticipates that the biopharmaceutical company will post […]

Liposomal Doxorubicin Volume Analysis, Segments, Value Share and Key Trends 2021-2030

By HealthClot Moderator
March 1, 2021
0

Liposomal Doxorubicin Volume Analysis, Segments, Value Share and Key Trends 2021-2030 Growth Prospects of the Global Liposomal Doxorubicin Market The comprehensive study on the Liposomal Doxorubicin market provides crucial insights to the stakeholders who are vying to solidify their presence in the current and future market landscape. The various factors that are likely to shape […]

By HealthClot Moderator
March 1, 2021
0

Q2 2021 EPS Estimates for Genmab A/S (NASDAQ:GMAB) Decreased by Truist Securiti Genmab A/S (NASDAQ:GMAB) – Stock analysts at Truist Securiti dropped their Q2 2021 earnings per share (EPS) estimates for Genmab A/S in a note issued to investors on Thursday, February 25th. Truist Securiti analyst A. Goonewardene now forecasts that the company will post […]

HealthClot